Evidence map›Paper›PMID 25222273›Full record

ArticlePloS one2014

Identification of unprecedented anticancer properties of high molecular weight biomacromolecular complex containing bovine lactoferrin (HMW-bLf).

Fawzi Ebrahim, Jayanth Suryanarayanan Shankaranarayanan, Jagat R Kanwar, Sneha Gurudevan, Uma Maheswari Krishnan, Rupinder K Kanwar

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.6field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 40 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Evaluation of Milk Colostrum Derived Lactoferrin of Sahiwal (International journal of molecular sciences · 2019
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Fawzi EbrahimNanomedicine-Laboratory of Immunology and Molecular Biomedical Research, School of Medicine, Faculty of Health, Deakin University, Geelong, Victoria, Australia.
Jayanth Suryanarayanan ShankaranarayananNanomedicine-Laboratory of Immunology and Molecular Biomedical Research, School of Medicine, Faculty of Health, Deakin University, Geelong, Victoria, Australia.
Jagat R KanwarNanomedicine-Laboratory of Immunology and Molecular Biomedical Research, School of Medicine, Faculty of Health, Deakin University, Geelong, Victoria, Australia.
Sneha GurudevanNanomedicine-Laboratory of Immunology and Molecular Biomedical Research, School of Medicine, Faculty of Health, Deakin University, Geelong, Victoria, Australia.
Uma Maheswari KrishnanCentre for Nanotechnology & Advanced Biomaterials (CeNTAB), School of Chemical & Biotechnology, SASTRA University, Thanjavur, India.
Rupinder K KanwarNanomedicine-Laboratory of Immunology and Molecular Biomedical Research, School of Medicine, Faculty of Health, Deakin University, Geelong, Victoria, Australia.
Deakin University · AUSASTRA University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the successful clinical trials, multifunctional glycoprotein bovine lactoferrin is gaining attention as a safe nutraceutical and biologic drug targeting cancer, chronic-inflammatory, viral and microbial diseases. Interestingly, recent findings that human lactoferrin oligomerizes under simulated physiological conditions signify the possible role of oligomerization in the multifunctional activities of lactoferrin molecule during infections and in disease targeting signaling pathways. Here we report the purification and physicochemical characterization of high molecular weight biomacromolecular complex containing bovine lactoferrin (≥250 kDa), from bovine colostrum, a naturally enriched source of lactoferrin. It showed structural similarities to native monomeric iron free (Apo) lactoferrin (∼78-80 kDa), retained anti-bovine lactoferrin antibody specific binding and displayed potential receptor binding properties when tested for cellular internalization. It further displayed higher thermal stability and better resistance to gut enzyme digestion than native bLf monomer. High molecular weight bovine lactoferrin was functionally bioactive and inhibited significantly the cell proliferation (p<0.01) of human breast and colon carcinoma derived cells. It induced significantly higher cancer cell death (apoptosis) and cytotoxicity in a dose-dependent manner in cancer cells than the normal intestinal cells. Upon cellular internalization, it led to the up-regulation of caspase-3 expression and degradation of actin. In order to identify the cutting edge future potential of this bio-macromolecule in medicine over the monomer, its in-depth structural and functional properties need to be investigated further.

Indexed as

Dietary SupplementsActinsAnimalsAntineoplastic AgentsApoptosisBreast NeoplasmsCaspase 3CattleCell Line, TumorCell ProliferationColonic NeoplasmsHumansLactoferrinUp-RegulationActinsAntineoplastic AgentsCaspase 3Lactoferrin

Identifiers

PMID25222273
PMCPMC4164354
OpenAlexW2011851322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.